What Pharmaxis Group does

Pharmaxis Group is a privately held, US-headquartered pharmaceutical distribution and logistics company focused on cross-border access to non-registered, unavailable, discontinued, or short-supply medicines, with an explicit emphasis on orphan and low-prevalence disease treatments. Headquartered in Coral Gables, Florida, with a second US office in Wilmington, North Carolina, the company maintains operations-support presence across Mexico, Colombia, Australia, India, Germany, and the United Kingdom. It serves a horizontal set of B2B and institutional buyers: hospitals and healthcare providers, government health authorities, wholesalers and distributors, medicine importers, specialized pharmacies, and patient support organizations.

The company operates three interconnected services: Named Patient Supply (enabling healthcare professionals to import non-registered medicines on behalf of specific patients), Medicines Shortages Supply (sourcing alternatives when drugs are discontinued or in short supply), and Logistics and Distribution (import/export execution, customs and regulatory adaptation, and cold chain handling). Its operational backbone is a network of GMP-certified international suppliers and CACA/BPA-certified logistics partners, validated cold chain containers maintaining 2–8°C for up to 120 hours, and warehousing positioned in Free Trade Zones. Notably, the company explicitly does not handle registered medicines, positioning itself in the regulatory white space of unlicensed and managed-access pathways.

Commercially, Pharmaxis Group runs a sales-led, direct B2B motion supplemented by a channel-partner model connecting manufacturers to end-users. Revenue is generated on a transaction-fee basis across all three service lines, with pricing undisclosed and quote-based per engagement. Go-to-market is bottom-of-funnel and inquiry-driven, operated through multilingual (English, Spanish, Portuguese) website contact forms for product enquiries, named patient supply, shortage requests, and supplier onboarding. The firm reports 11–50 employees and shows no app, API, or software product surface despite a "SaaS/Marketplace" self-description in firmographic metadata.

Name

Pharmaxis Group

Legal name

Pharmaxis Group

Website

https://pharmaxisgroup.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

US-based pharmaceutical distributor providing cross-border access to non-registered, orphan, and short-supply medicines via named patient supply, shortages sourcing, and cold chain logistics for hospitals, governments, wholesalers, and specialized pharmacies worldwide.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution and Logistics

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

akta.pro secondary industry

Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)

Keywords

• Pharmaceutical distribution services
• Cold chain logistics
• Named patient supply
• Orphan disease medicines
• Medicines shortage sourcing

Headquarters

HQ city

Coral Gables

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

1. Named Patient Supply: Enabling healthcare professionals to access non-registered medicines on behalf of their patients, serving orphan and low-prevalence disease treatments.
2. Medicines Shortages Supply: Sourcing globally to healthcare providers, wholesalers, distributors when medicines are discontinued, in short supply, or not available in patient's country.
3. Logistics and Distribution: Import and export services with specialized expertise for pharmaceutical products including room temperature, cold chain, and controlled medications. Connecting pharmaceutical industry with end-users worldwide.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels2 records

Core offering

Pharmaxis Group is a US-based pharmaceutical distribution and logistics company that supplies non-registered, orphan, and low-prevalence disease medicines to healthcare providers, governments, wholesalers, and patient support organizations worldwide. The company operates through three interconnected service lines: Named Patient Supply, Medicines Shortages Supply, and Logistics and Distribution, leveraging GMP-certified suppliers, cold chain capabilities, and Free Trade Zone warehousing to deliver pharmaceuticals globally.

Product overview

Pharmaxis Group is a pharmaceutical distribution and logistics company offering three interconnected services: Named Patient Supply, Medicines Shortages Supply, and Logistics and Distribution. The company focuses on closing the gap between patients needing orphan or low-prevalence disease treatments and pharmaceutical manufacturers worldwide. Named Patient Supply allows healthcare professionals to access non-registered medicines on behalf of patients; Medicines Shortages Supply helps source alternatives during shortages; and Logistics and Distribution provides the international shipping, cold chain management, and regulatory compliance infrastructure that underpins both services.

Differentiator

Problem solved

Functional benefit

Products and services

• Named Patient Supply Enables healthcare professionals to access non-registered medicines on behalf of their patients, providing worldwide access to high-quality pharmaceutical products not available in the patient's country. Targets hospitals, clinics, and healthcare providers serving patients with orphan or low-prevalence diseases.
• Medicines Shortages Supply Helps healthcare providers, governments, and distributors source alternative medicines when facing shortages, connecting patients with needed therapies through a global supplier network. Activated during essential drug shortages affecting patient treatments.
• Logistics and Distribution Provides specialized import and export services for pharmaceutical products, including cold chain management, controlled medications handling, and coordination with regulatory and customs requirements across multiple countries. Serves as the operational backbone for both Named Patient and Shortages Supply offerings.

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• GMP-Certified International SupplierscoreTechnology or IntegrationNetwork of international suppliers certified in Good Manufacturing Practices (GMP) for secondary conditioning of drugs with active ingredients and sterile and non-sterile pharmaceutical forms.
• CACA and BPA Certified Strategic PartnerscoreTechnology or IntegrationCertified strategic partners in Certificate of Storage and Conditioning Capacity (CACA) and Good Storage Practices (BPA) for managing distribution of products with specialized requirements including room temperature, cold chain, and controlled medications.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Eurocept International: European specialty pharma group with named-patient and unlicensed medicine distribution arms — comparable cross-border specialty pharma distribution model.
• Clinigen Group: UK-listed global leader in managed access / named patient supply and unlicensed medicine distribution — directly comparable to Pharmaxis's Named Patient Supply and Medicines Shortages Supply services across multiple geographies.
• Durbin PLC: UK-based pharmaceutical distributor with a dedicated unlicensed medicines division supplying named-patient and shortage medicines globally — closely overlaps with Pharmaxis's supply and distribution activities.
• WEP Clinical: Specialist in named patient supply and expanded access programs for unlicensed and investigational medicines, serving pharma manufacturers and healthcare providers globally — a close functional analogue to Pharmaxis's core offering.
• BAP Pharma: UK-headquartered unlicensed and investigational medicine supplier serving hospitals and patients worldwide — comparable niche focus on hard-to-source pharmaceuticals through named-patient and managed-access channels.
• MyTomorrows: Amsterdam-based platform enabling pre-approval and managed access to medicines not yet commercially available — directly comparable to Pharmaxis's Named Patient Supply service targeting unmet patient needs.
• Primex Pharmaceuticals: Finnish specialty pharma company operating a global named patient supply network for anesthesia and orphan therapeutics — directly analogous business model of cross-border unlicensed medicine distribution.

Broad incumbents

• Almac Group: Large global contract pharmaceutical services and distribution provider with cold-chain and clinical-trial supply capabilities — broader portfolio but overlapping specialty distribution and temperature-controlled logistics.
• Cencora (formerly AmerisourceBergen): One of the largest US pharmaceutical distributors with global specialty distribution and consulting services — broad incumbent with overlapping reach in specialty and orphan pharmaceutical distribution.
• McKesson: Global pharmaceutical distributor with a specialty and biotech distribution business serving manufacturers and providers worldwide — broad incumbent whose specialty division is adjacent to Pharmaxis's niche.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pharmaxis-group

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaxis Group